These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38787638)

  • 1. Exploring the mechanism of action of spirooxindoles as a class of CDK2 inhibitors: a structure-based computational approach.
    Abdjan MI; Shafiq M; Nerukh D; Nur-E-Alam M; Ul-Haq Z
    Phys Chem Chem Phys; 2024 Jun; 26(22):16139-16152. PubMed ID: 38787638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
    Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
    Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations.
    Chen J; Pang L; Wang W; Wang L; Zhang JZH; Zhu T
    J Biomol Struct Dyn; 2020 Mar; 38(4):985-996. PubMed ID: 30843759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
    Tripathi SK; Muttineni R; Singh SK
    J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
    Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
    Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accurate Prediction of Complex Structure and Affinity for a Flexible Protein Receptor and Its Inhibitor.
    Bekker GJ; Kamiya N; Araki M; Fukuda I; Okuno Y; Nakamura H
    J Chem Theory Comput; 2017 Jun; 13(6):2389-2399. PubMed ID: 28482660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
    El-Naggar AM; El-Hashash MA; Elkaeed EB
    Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights.
    Al-Sanea MM; Obaidullah AJ; Shaker ME; Chilingaryan G; Alanazi MM; Alsaif NA; Alkahtani HM; Alsubaie SA; Abdelgawad MA
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33466812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C
    Helal MH; Owda ME; Mogharbel AT; Hamzah Alessa A; Omer N; Abdelaziz MA; Ibrahim I; Eliwa EM
    Bioorg Chem; 2024 Feb; 143():107091. PubMed ID: 38183683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting cyclin-dependent kinase 2 CDK2: Insights from molecular docking and dynamics simulation - A systematic computational approach to discover novel cancer therapeutics.
    Chagaleti BK; B SK; G V A; Rajagopal R; Alfarhan A; Arockiaraj J; Muthu Kumaradoss K; Karthick Raja Namasivayam S
    Comput Biol Chem; 2024 Oct; 112():108134. PubMed ID: 38964206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
    Pasha FA; Neaz MM
    J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.
    Hylsová M; Carbain B; Fanfrlík J; Musilová L; Haldar S; Köprülüoğlu C; Ajani H; Brahmkshatriya PS; Jorda R; Kryštof V; Hobza P; Echalier A; Paruch K; Lepšík M
    Eur J Med Chem; 2017 Jan; 126():1118-1128. PubMed ID: 28039837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations.
    Eldehna WM; El Hassab MA; Abo-Ashour MF; Al-Warhi T; Elaasser MM; Safwat NA; Suliman H; Ahmed MF; Al-Rashood ST; Abdel-Aziz HA; El-Haggar R
    Bioorg Chem; 2021 May; 110():104748. PubMed ID: 33684714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.